The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...
The delay follows leadership changes within the FDA. Dr. Scott Steele has been appointed acting director of the agency’s ...
The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has ...
Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...
The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's ...
Novavax started the week hoping the FDA would issue a full approval of its Covid vaccine. But the decision never came.
The FDA was scheduled to release its decision on Novavax’s updated, protein-based COVID-19 vaccine on April 1.
The agency is sitting on a decision to grant full approval for Novavax’s shot, days after top vaccine regulator pushed out.
Novavax's COVID-19 vaccine received FDA Emergency Use Authorization, but full approval faces delays as regulators request more data beyond the April 1 deadline.
The delay dovetails with moves by Republican lawmakers in at least seven states to ban or limit mRNA vaccines. Some, according to KFF Health News, are also pressing regulators to revoke federal ...
The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's ...
The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...